BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Asklepios BioPharmaceutical, Inc. And Bayer Healthcare, LLC Announce Collaboration On Gene Therapy For The Treatment Of Hemophilia


10/19/2005 5:10:00 PM

BERKELEY, Calif. & CHAPEL HILL, N.C.--(BUSINESS WIRE)--May 18, 2005--Bayer HealthCare, LLC, Biological Products Division (Bayer BP), and Asklepios Biopharmaceutical Inc. (AskBio), a private development-stage biotechnology company, announced today they have entered into an early-stage research and collaboration agreement to evaluate gene therapy for the treatment of hemophilia B. Pending positive results of a feasibility study, this collaboration could lead to a joint development and commercialization agreement between Bayer BP and AskBio for the novel gene therapy treatment for hemophilia B. "We are looking forward to working closely with one of the world's most respected and innovative health care companies. Bayer HealthCare has a long-standing and proactive commitment to providing innovative and life-saving treatment. This important collaboration facilitates the first steps toward a combined platform of expertise and resources jointly focused on advancing care for the global hemophilia community," said Sheila Mikhail, CEO of AskBio.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->